공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

인유두종 바이러스 E7 단백질 : 파이프라인 리뷰

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 409620
페이지 정보 영문 156 Pages
가격
US $ 3,500 ₩ 3,894,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,788,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,682,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인유두종 바이러스 E7 단백질 : 파이프라인 리뷰 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 156 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

인유두종 바이러스 E7 단백질을 표적으로 한 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 최신 뉴스 및 발표와 함께 정리하여 전해드립니다.

서론

  • 조사 범위

인유두종 바이러스 E7 단백질 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품의 개요

  • 후기 단계 제품
  • 초기 단계 제품
  • 개발 단계 불명의 제품

기업에서 개발중인 제품

대학/기관에서 개발중인 제품

치료제 평가

  • 단일요법/병용 치료제의 경우
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Abion Inc
  • Advaxis Inc
  • Bioleaders Corporation
  • BioNTech AG
  • Cancer Research Technology Ltd
  • Etubics Corp
  • Formune SL
  • Genexine Inc
  • Genticel S.A.
  • iBio Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • Kite Pharma Inc
  • MedImmune LLC
  • Selecta Biosciences Inc
  • Tomegavax Inc
  • Transgene SA
  • VLPbio

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

KSA 17.01.04

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abion Inc, H2 2019
  • Pipeline by Advaxis Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Bioleaders Corp, H2 2019
  • Pipeline by BioNTech SE, H2 2019
  • Pipeline by Cellid Co Ltd, H2 2019
  • Pipeline by Cue Biopharma Inc, H2 2019
  • Pipeline by Etubics Corp, H2 2019
  • Pipeline by Genexine Inc, H2 2019
  • Pipeline by Hookipa Pharma Inc, H2 2019
  • Pipeline by iBio Inc, H2 2019
  • Pipeline by Immunomic Therapeutics Inc, H2 2019
  • Pipeline by IMV Inc, H2 2019
  • Pipeline by Innovene, H2 2019
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2019
  • Pipeline by Oxford Vacmedix UK Ltd, H2 2019
  • Pipeline by Papivax LLC, H2 2019
  • Pipeline by Selecta Biosciences Inc, H2 2019
  • Pipeline by Touchlight Genetics Ltd, H2 2019
  • Pipeline by Transgene SA, H2 2019
  • Pipeline by UbiVac LLC, H2 2019
  • Pipeline by ViciniVax BV, H2 2019
  • Pipeline by Vir Biotechnology Inc, H2 2019
  • Pipeline by VLP The Vaccines Company SL, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019

Summary

Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 44 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The latest report Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2019, outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host inteferon alpha. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 4, 1, 11 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 4, 7 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Infectious Disease and Gastrointestinal which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Anal Cancer, Oropharyngeal Cancer, Head And Neck Cancer, Human Papillomavirus Infections, Penile Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer, Vulvar Cancer, Anal Dysplasia, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Cancer, Rectal Cancer and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)
  • The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Human Papillomavirus Protein E7 (E7) - Overview
  • Human Papillomavirus Protein E7 (E7) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development
  • Abion Inc
  • Advaxis Inc
  • AstraZeneca Plc
  • Bioleaders Corp
  • BioNTech SE
  • Cellid Co Ltd
  • Cue Biopharma Inc
  • Etubics Corp
  • Genexine Inc
  • Hookipa Pharma Inc
  • iBio Inc
  • Immunomic Therapeutics Inc
  • IMV Inc
  • Innovene
  • Inovio Pharmaceuticals Inc
  • Oxford Vacmedix UK Ltd
  • Papivax LLC
  • Selecta Biosciences Inc
  • Touchlight Genetics Ltd
  • Transgene SA
  • UbiVac LLC
  • ViciniVax BV
  • Vir Biotechnology Inc
  • VLP The Vaccines Company SL
  • Human Papillomavirus Protein E7 (E7) - Drug Profiles
  • (bizalimogene ralaplasmid + mavilimogene ralaplasmid) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABI-231 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABN-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Human Papillomavirus Protein E7 (E7) - Dormant Products
  • Human Papillomavirus Protein E7 (E7) - Discontinued Products
  • Human Papillomavirus Protein E7 (E7) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q